AnaptysBio: Trial of Jemperli Drug Meets Primary Endpoint

By Dean Seal

AnaptysBio Inc. said Friday that a recent trial studying endometrial cancer treatment dostarlimab, known by the brand name Jemperli, met its primary endpoint of investigator-assessed progression-free survival.

The San Diego, Calif., clinical-stage biotechnology company reported that GSK PLC's Phase 3 trial, which treated chemotherapy patients with advanced or recurrent endometrial cancer, showed that Jemperli provided a statistically significant and clinically meaningful progression-free survival benefit in a prespecified subgroup of patients who were mismatch-repair deficient and microsatellite instability-high.

Jemperli also provided a benefit in progression-free survival for a subgroup of patients who were mismatch-repair proficient and microsatellite stable, AnaptysBio said.

Although overall survival data is still premature at this time, the company said a favorable trend was observed in the overall population.

Regulatory submissions based on the trials are expected in the first half of 2023, the company said.

Jemperli was discovered by AnaptysBio and licensed to Tesaro Inc., now a part of GSK, under a collaboration and exclusive license agreement signed in March 2014.

AnaptysBio's shares were up 2.9% to $28.07 in premarket trading Friday.

Write to Dean Seal at [e-mail]

(END) Dow Jones Newswires

December 02, 2022 09:56 ET (14:56 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.